Houston-based pharmaceutical company Moleculin Biotech, Inc. is making strides in the development of drug candidates for the treatment of cancers and viruses. Its Annamycin drug candidate is currently in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia and cancers that have metastasized to the lungs. Moleculin's flagship immune/transcription modulator, WP1066, is currently in Phase I clinical trials to treat brain tumors, pediatric brain tumors, pancreatic cancer, and other malignancies. The company is also working on WP1220, an analog of WP1066 intended for topical treatment of cutaneous T-cell lymphoma, and WP1122, which will target glioblastoma multiforme and COVID-19. Since its incorporation in 2015, Moleculin has established itself as a significant player in the biotech industry.
Moleculin Biotech, Inc.'s ticker is MBRX
The company's shares trade on the NASDAQ stock exchange
They are based in Houston, Texas
There are 11-50 employees working at Moleculin Biotech, Inc.
It is https://www.moleculin.com/
Moleculin Biotech, Inc. is in the Healthcare sector
Moleculin Biotech, Inc. is in the Biotechnology industry
The following five companies are Moleculin Biotech, Inc.'s industry peers: